Eisai Clinical Trials

Clinical Trial Search

Find trials of interest to you, by directly searching using a known Registry # (NCT or EudraCT), or indirectly using the advanced search.

  • Keywords

  • Drug Name

  • Study Phase

  • Indication

  • Country

  • Protocol #

  • Registry #

Reset
73 Studies Found
(based on current selection)

Search Results

73 Results found. Modify your search

Compare specific studies, click your study of interest or modify your search criteria.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome

Registry #: NCT04572243

Protocol #: E2023-A001-304

Listed on CSDR.com

View study

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacodynamics of Lemborexant in Korean Subjects With Insomnia Disorder

Registry #: NCT05594589

Protocol #: E2006-J082-204

Listed on CSDR.com

View study

An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer’s Disease

Registry #: NCT04971733, 2020-005728-12

Protocol #: E2814-G000-103

Listed on CSDR.com

View study

A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Registry #: NCT03173560, 2016-002778-11

Protocol #: E7080-G000-218

Listed on CSDR.com

View study

An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

Registry #: NCT03477175, 2017-003668-11

Protocol #: E7080-G000-604

Listed on CSDR.com

View study

A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)

Registry #: NCT04763408, EUPAS36854

Protocol #: E7080-M000-508

Listed on CSDR.com

View study

A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Registry #: NCT03250676, 2018-000570-29

Protocol #: H3B-6545-A001-101

Listed on CSDR.com

View study

A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE)

Registry #: NCT04154189, 2019-003696-19

Protocol #: E7080-G000-230

Listed on CSDR.com

View study

A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma

Registry #: NCT03418922, JapicCTI-183850, jRCT2080223794

Protocol #: E7080-J081-117

Listed on CSDR.com

View study

An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma

Registry #: NCT03006926, 2018-000522-55, JapicCTI-173494, jRCT2080223439

Protocol #: E7080-J081-116

Listed on CSDR.com

View study

An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy

Registry #: NCT02914314, 2013-005391-17

Protocol #: E2007-G000-238

Listed on CSDR.com

View study

An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas – INSTAL-101

Registry #: NCT04144140, 2019-000160-17

Protocol #: E7766-G000-101

Listed on CSDR.com

View study

Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Registry #: NCT02501096, 2017-000300-26

Protocol #: E7080-A001-111

Listed on CSDR.com

View study

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Registry #: NCT03245151, 2022-003736-77

Protocol #: E7080-A001-216

Listed on CSDR.com

View study

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

Registry #: NCT02834780, 2016-001915-19

Protocol #: H3B-6527-G000-101

Listed on CSDR.com

View study

Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Registry #: NCT02432274, 2013-005534-38

Protocol #: E7080-G000-207

Listed on CSDR.com

View study

An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson’s Disease Dementia With or Without Amyloid Copathology

Registry #: NCT04764669

Protocol #: E2027-A001-203

Listed on CSDR.com

View study

A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies

Registry #: NCT03467152, 2017-003728-64, JapicCTI-183932

Protocol #: E2027-G000-201

Listed on CSDR.com

View study

A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors

Registry #: NCT03245450, 2016-003352-67, SNCTP000004098

Protocol #: E7389-G000-213

Listed on CSDR.com

View study

A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures) (FREEDOM Study)

Registry #: NCT03201900, 2019-003734-17, JapicCTI-173644

Protocol #: E2007-J000-342

Listed on CSDR.com

View study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

Registry #: NCT02783729, 2015-004347-39

Protocol #: E2006-G000-304

Listed on CSDR.com

View study

A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder (SUNRISE 2)

Registry #: NCT02952820, 2015-001463-39

Protocol #: E2006-G000-303

Listed on CSDR.com

View study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer’s Disease Dementia

Registry #: NCT03001557, 2017-003306-40, jRCT2080223437, JAPICCTI-173492

Protocol #: E2006-G000-202

Listed on CSDR.com

View study

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer’s Disease

Registry #: NCT02956486, 2016-003928-23

Protocol #: E2609-G000-301

Listed on CSDR.com

View study

A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal Alzheimer’s Disease) and Mild to Moderate Dementia Due to Alzheimer’s Disease

Registry #: NCT02322021

Protocol #: E2609-G000-202

Listed on CSDR.com

View study

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer’s Disease

Registry #: NCT02956486, EU CTR 2016-004128-42

Protocol #: E2609-G000-302

Listed on CSDR.com

View study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Registry #: NCT01995838

Protocol #: E2006-G000-201

Listed on CSDR.com

View study

An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

Registry #: NCT02513472

Protocol #: E7389-M001-218

Listed on CSDR.com

View study

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Registry #: NCT00416195, 2006-003702-26

Protocol #: E2007-G000-208

Listed on CSDR.com

View study

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Registry #: NCT01278407

Protocol #: E2020-J081-341

Listed on CSDR.com

View study

Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies – Phase II

Registry #: NCT00543855

Protocol #: E2020-J081-431

Listed on CSDR.com

View study

An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Registry #: NCT02225470

Protocol #: E7389-C086-304

Listed on CSDR.com

View study

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Registry #: NCT02481050

Protocol #: E7389-M001-216

Listed on CSDR.com

View study

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Registry #: NCT01151540, 2016-004953-34

Protocol #: E2080-J081-305

Listed on CSDR.com

View study

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients

Registry #: NCT01146951, 2016-004952-30

Protocol #: E2080-J081-304

Listed on CSDR.com

View study

The “EMBRACE” Trial: Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus “Treatment of Physician’s Choice” in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Registry #: NCT00388726, 2006-001949-34

Protocol #: E7389-G000-305

Listed on CSDR.com

View study

Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer

Registry #: NCT00965523, JapicCTI-080561

Protocol #: E7389-J081-224

Listed on CSDR.com

View study

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Registry #: NCT00337103, 2005-004009-26

Protocol #: E7389-G000-301

Listed on CSDR.com

View study

A 24-week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson’s Disease Patients with Dementia.

Registry #: NCT00165815

Protocol #: E2020-E044-316

Listed on CSDR.com

View study

Phase II Clinical Study of E7389 for Locally Advanced or Metastatic Breast Cancer

Registry #: NCT00633100, JapicCTI-080561

Protocol #: E7389-J081-221

Listed on CSDR.com

View study

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Registry #: NCT02427607, 2016-004945-10

Protocol #: E2007-J000-341

Listed on CSDR.com

View study

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer’s Disease

Registry #: NCT00478205, 2006-004888-54

Protocol #: E2020-G000-326

Listed on CSDR.com

View study

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan.

Registry #: Not available

Protocol #: E2020-J081-161

Listed on CSDR.com

View study

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) in the Management of Patients with Alzheimer’s Disease in a Nursing Home Facility

Registry #: Not available

Protocol #: E2020-A001-311

Listed on CSDR.com

View study

A Preliminary, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

Registry #: Not available

Protocol #: E2020-A001-201

Listed on CSDR.com

View study

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Registry #: NCT00165659

Protocol #: E2020-J081-231

Listed on CSDR.com

View study

A 54-week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer’s Disease.

Registry #: Not available

Protocol #: E2020-A001-312

Listed on CSDR.com

View study

A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

Registry #: Not available

Protocol #: E2020-A044-304

Listed on CSDR.com

View study

A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

Registry #: Not available

Protocol #: E2020-A001-302

Listed on CSDR.com

View study

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer’s Disease

Registry #: NCT01404169

Protocol #: E2020-C086-339

Listed on CSDR.com

View study

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer’s Disease Followed by a 12 Week Open-Label Extension Period

Registry #: NCT00096473

Protocol #: E2020-A001-315

Listed on CSDR.com

View study

A 15-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

Registry #: Not available

Protocol #: E2020-A001-301

Listed on CSDR.com

View study

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures

Registry #: NCT01161524, 2010-018518-56

Protocol #: E2007-G000-235

Listed on CSDR.com

View study

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Registry #: NCT00144690, 2005-004199-18

Protocol #: E2007-A001-206

Listed on CSDR.com

View study

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Registry #: NCT00700310, 2007-006169-33

Protocol #: E2007-G000-306

Listed on CSDR.com

View study

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Registry #: NCT00699582, 2007-006168-31

Protocol #: E2007-G000-305

Listed on CSDR.com

View study

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Registry #: NCT00699972, 2007-006191-11, EMEA-000467-PIP01-08

Protocol #: E2007-G000-304

Listed on CSDR.com

View study

A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Registry #: NCT01618695, 2020-002109-24, JapicCTI-121906, CTR20131839, jRCT2081211861

Protocol #: E2007-J000-335

Listed on CSDR.com

View study

Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Registry #: NCT00946153, JapicCTI-101007, jRCT2080220974

Protocol #: E7080-J081-202

Listed on CSDR.com

View study

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Registry #: NCT01761266, JapicCTI-132113, jRCT2080222067, 2012-002992-33

Protocol #: E7080-G000-304

Listed on CSDR.com

View study

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma

Registry #: NCT01458249, JapicCTI-111677

Protocol #: E7389-J081-217

Listed on CSDR.com

View study

Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Registry #: NCT00413192, 2005-004272-20

Protocol #: E7389-E044-207

Listed on CSDR.com

View study

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Registry #: NCT01327885, 2010-024483-17

Protocol #: E7389-G000-309

Listed on CSDR.com

View study

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Registry #: NCT01405053, 2010-023505-36

Protocol #: E2080-G000-303

Listed on CSDR.com

View study

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Registry #: NCT01136733, EU CTR 2010-019484-10

Protocol #: E7080-G000-205 Ph2

Listed on CSDR.com

View study

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Registry #: NCT01136733, 2010-019484-10

Protocol #: E7080-G000-205

Listed on CSDR.com

View study

A Phase 1 Study of E7080 in Subjects With Solid Tumor

Registry #: NCT01268293, JapicCTI-111382, jRCT2080221345

Protocol #: E7080-J081-105

Listed on CSDR.com

View study

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Registry #: NCT00280397, JapicCTI-070435, jRCT2080220426

Protocol #: E7080-J081-103

Listed on CSDR.com

View study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Registry #: NCT01321554, JapicCTI-111573, jRCT2080221533, 2010-023783-41

Protocol #: E7080-G000-303

Listed on CSDR.com

View study

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Registry #: NCT01393743, EU CTR 2011-000265-12

Protocol #: E2007-G000-332 EXT

Listed on CSDR.com

View study

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Registry #: NCT01393743, 2011-000265-12, JapicCTI-121774, jRCT2080211732

Protocol #: E2007-G000-332

Listed on CSDR.com

View study

A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer

Registry #: NCT01728623, JapicCTI-122009, jRCT2080221963

Protocol #: E7080-J081-208

Listed on CSDR.com

View study

Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Registry #: NCT00784303, 2007-005933-12

Protocol #: E7080-G000-201

Listed on CSDR.com

View study